Vistide

Vistide Uses, Dosage, Side Effects, Food Interaction and all others data.

Vistide is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis. It was manufactured by Gilead and initially approved by the FDA in 1996, but has since been discontinued.

Vistide is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Vistide suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis.

Table Of contents

• Vistide
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Vistide
Availability	Prescription only
Generic	Cidofovir
Cidofovir Other Names	Cidofovir, Cidofovirum
Related Drugs	ganciclovir ophthalmic, valganciclovir, Valcyte, foscarnet, Cytovene
Weight	75mg/ml,
Type	Intravenous solution
Formula	C8H14N3O6P
Weight	Average: 279.187 Monoisotopic: 279.062021707
Protein binding	6%
Groups	Approved
Therapeutic Class
Manufacturer	Gilead Sciences International Ltd
Available Country	United States, France, Netherlands, Portugal, Spain,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Vistide is an antiviral agent used to treat Cytomegalovirus (CMV) retinitis in patients with AIDS.

For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

Vistide is also used to associated treatment for these conditions: Cytomegalovirus Retinitis, Herpes Simplex Virus, Monkeypox, Smallpox

How Vistide works

Vistide acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Vistide diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis.

Toxicity

Kidney damage, fall in the number of white blood cells, decreased platelets

Food Interaction

No interactions found.

Vistide Drug Interaction

Unknown: aripiprazole, aripiprazole, aspirin, aspirin, amphetamine / dextroamphetamine, amphetamine / dextroamphetamine, aspirin, aspirin, diltiazem, diltiazem, diltiazem, diltiazem, sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprim, albuterol / ipratropium, albuterol / ipratropium, meperidine, meperidine, cholecalciferol, cholecalciferol

Vistide Disease Interaction

Major: dehydration, neutropenia, renal dysfunction

Volume of Distribution

• 537 ± 126 mL/kg [VISTIDE ADMINISTERED WITHOUT PROBENECID]
• 410 ± 102 mL/kg [VISTIDE ADMINISTERED WITH PROBENECID]

Elimination Route

100%

Half Life

2.4 to 3.2 hours

Clearance

• 179 +/- 23.1 mL/min/1.73 m2 [WITHOUT PROBENECID]
• 148 +/- 38.8 mL/min/1.73 m2 [WITH PROBENECID]

Innovators Monograph

You find simplified version here Vistide